Suppliers / Inke

Inke

Spain 2 duplicate records merged Updated 9 July 2026

Inke is an API manufacturer based in Spain. It holds 48 active US drug master files across a filed portfolio of 21 molecules. Its most recent recorded inspection, by US FDA, closed on 15 March 2023 as VAI.

48
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 15 March 2023 VAI US FDA
  • 10 April 2019 VAI US FDA
  • 15 April 2016 NAI US FDA
  • 25 January 2013 VAI US FDA
  • 25 July 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Spain, Spain 3003663245

What they file, and where

Molecule Regulators Docs
Arformoterol US FDA 4
Granisetron US FDA 4
Ondansetron US FDA 4
Aclidinium Bromide US FDA 2
Aprepitant US FDA 2
Clevidipine US FDA 2
Fluconazole US FDA 2
Formoterol US FDA 2
Glycopyrronium US FDA 2
Indacaterol US FDA 2
Show all 21 molecules on file
Olanzapine US FDA 2
Olodaterol US FDA 2
Revefenacin US FDA 2
Risperidone US FDA 2
Rizatriptan US FDA 2
Salmeterol US FDA 2
Tetrabenazine US FDA 2
Tiotropium US FDA 2
Umeclidinium Bromide US FDA 2
Vilanterol US FDA 2
Zolmitriptan US FDA 2

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. Inke comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was VAI, on 15 March 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability